Advertisment

New Embolization Process: A Game-Changer in the Treatment of Subdural Hematoma

author-image
Ethan Sulliva
New Update
New Embolization Process: A Game-Changer in the Treatment of Subdural Hematoma

New Embolization Process: A Game-Changer in the Treatment of Subdural Hematoma

Advertisment

Three new randomized control trials have shed light on a promising new embolization process in the treatment of subdural hematoma. This revolutionary endovascular procedure has been found to significantly reduce the need for surgery, offering a major breakthrough in managing this condition.

Advertisment

Understanding the Embolization Process

The embolization process focuses on the middle meningeal artery (MMA). This artery has been identified as a key player in the recurrence of chronic or subacute subdural hematoma. The procedure involves injecting a substance to block the artery, thereby preventing continued bleeding into the subdural space. The embolization process is performed alongside surgery to remove pooled blood.

Landmark Trials and Results

Advertisment

Landmark trials involving the Onyx and Squid liquid embolic systems have reported consistent findings that favor embolization. The EMBOLISE trial showed that embolization with the Onyx system significantly reduced recurrence or progression of subdural hematoma compared to surgery alone. Serious adverse events related to the embolization procedure were low, and embolization achieved technical success in all cases. The MAGIC MT trial from China also reported a reduction in symptomatic recurrence or progression of subdural hematoma with MMA embolization using Onyx.

Benefits of the Embolization Process

This innovative treatment offers a less invasive alternative to traditional surgery, significantly reducing the failure rates of traditional surgical and non-surgical management strategies. The Onyx and Squid liquid embolic systems have proven effective in diminishing recurrence rates, with a number needed to treat (NNT) of around 14. The embolization process has shown a nearly threefold reduction in the need for repeat surgical drainage of the subdural hematoma.

Advertisment

Implications for the Future

This new approach to treating subdural hematoma stands to revolutionize how this condition is managed. The process has the potential to improve the quality of life for those suffering from subdural hematoma by reducing the need for invasive surgeries and subsequent complications. However, while the results from trials have been positive, no liquid embolic agent currently has FDA clearance for MMAE; regulatory review is pending.

As research continues to evolve in this area, it's clear that MMA embolization is an exciting development in the field. This promising new procedure offers hope to patients and medical professionals alike in the fight against subdural hematoma.

Subacute Subdural Hematoma
Advertisment
Chat with Dr. Medriva !